We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...
New late-stage study data shows that treatment with Amgen's Uplizna for a year improves disease symptoms in patients with ...
The phase 3 MINT trial evaluated the efficacy and safety of the drug in both muscle-specific kinase autoantibody ...
Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman and Gwen A. Melincoff, Board Member to Retire ...
A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps ...
inews.co.uk on MSN1d
The 3.5m people with rare diseases who face worsening treatment and diagnosis ratesRare diseases affect one in 17 people in the UK, but a Government initiative designed to improve their quality of life will ...
Rare diseases - a medical condition so obscure that even your doctor has to Google. Despite their name, these diseases ...
New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...
With thousands of rare diseases affecting millions of families worldwide, one Tampa Bay lawmaker is taking action to position Florida as a national leader in genetic medicine.
The bioengineered protein drugs market is experiencing a paradigm shift, with pharmaceutical and biotech companies leveraging advanced biopharmaceuti ...
We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...
With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback